Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $5.00 price objective on the stock. D. Boral Capital’s price objective would suggest a potential upside of 342.48% from the stock’s current price.
Separately, Wall Street Zen cut Hoth Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 21st. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $4.00.
Check Out Our Latest Stock Report on Hoth Therapeutics
Hoth Therapeutics Stock Down 3.4%
Hoth Therapeutics (NASDAQ:HOTH – Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.07. As a group, sell-side analysts expect that Hoth Therapeutics will post -1.36 earnings per share for the current year.
Institutional Trading of Hoth Therapeutics
A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC increased its stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH – Free Report) by 15.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,946 shares of the company’s stock after acquiring an additional 13,038 shares during the period. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 as of its most recent SEC filing. 7.08% of the stock is currently owned by institutional investors and hedge funds.
About Hoth Therapeutics
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
Featured Articles
- Five stocks we like better than Hoth Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- How to Buy Gold Stock and Invest in Gold
- 3 Stocks Hitting All-Time Highs With More Room to Run
- What is the FTSE 100 index?
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.